Skyler Bloom - ADMA Biologics Senior Strategy
| ADMA Stock | USD 9.55 0.07 0.74% |
Executive
Skyler Bloom is Senior Strategy of ADMA Biologics
| Address | 465 State Route 17, Ramsey, NJ, United States, 07446 |
| Phone | 201 478 5552 |
| Web | https://www.admabiologics.com |
ADMA Biologics Management Efficiency
The company has return on total asset (ROA) of 0.0851 % which means that it generated a profit of $0.0851 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0243) %, meaning that it created substantial loss on money invested by shareholders. ADMA Biologics' management efficiency ratios could be used to measure how well ADMA Biologics manages its routine affairs as well as how well it operates its assets and liabilities. As of June 2, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to 0.07. At present, ADMA Biologics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 269.9 M, whereas Other Assets are forecasted to decline to 0.95.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cindy Tahl | Fate Therapeutics | 51 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Rajani MD | Atara Biotherapeutics | N/A | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Shiva CPA | 89bio Inc | 58 | |
| Holli Kolkey | Arcus Biosciences | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Edward Berg | Vaxart Inc | 59 | |
| Robin Andrulevich | Sana Biotechnology | 58 | |
| Amanda Kurihara | 89bio Inc | N/A | |
| Tina Ventura | Madrigal Pharmaceuticals | N/A | |
| MD JD | Cidara Therapeutics | N/A | |
| John Bluth | BioCryst Pharmaceuticals | 51 | |
| Shiva Natarajan | 89bio Inc | 58 | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| SPHR CCP | Cidara Therapeutics | N/A | |
| Tracey Vetterick | Akebia Ther | N/A | |
| Carolyn Rucci | Akebia Ther | N/A | |
| Sean Tucker | Vaxart Inc | 55 | |
| Charles Gayer | BioCryst Pharmaceuticals | 53 | |
| Cindy JD | Fate Therapeutics | 51 | |
Management Performance
| Return On Equity | -0.0243 | ||||
| Return On Asset | 0.0851 |
ADMA Biologics Leadership Team
Elected by the shareholders, the ADMA Biologics' board of directors comprises two types of representatives: ADMA Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ADMA. The board's role is to monitor ADMA Biologics' management team and ensure that shareholders' interests are well served. ADMA Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ADMA Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, CFO VP | ||
| Michael Goldstein, Sr Counsel | ||
| Neal Fitzpatrick, Vice Sales | ||
| Kaitlin Kestenberg, Project Compliance | ||
| Cyndi Tolman, VP Services | ||
| Brian CPA, CFO VP | ||
| Dr DPS, CoFounder Chairman | ||
| Skyler Bloom, Senior Strategy | ||
| Cindy Petersen, Executive Resources | ||
| Adam Grossman, President CEO, Director | ||
| Drew Pantello, Vice Development | ||
| PharmD BCOP, Ex Engagement | ||
| Michael Least, VP Operations |
ADMA Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ADMA Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0243 | ||||
| Return On Asset | 0.0851 | ||||
| Profit Margin | (0.01) % | ||||
| Operating Margin | 0.27 % | ||||
| Current Valuation | 2.31 B | ||||
| Shares Outstanding | 231.81 M | ||||
| Shares Owned By Insiders | 2.84 % | ||||
| Shares Owned By Institutions | 77.81 % | ||||
| Number Of Shares Shorted | 8.44 M | ||||
| Price To Earning | (1.55) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ADMA Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ADMA Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Adma Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Adma Biologics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ADMA Biologics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is ADMA Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.02) | Revenue Per Share 1.255 | Quarterly Revenue Growth 0.439 | Return On Assets 0.0851 | Return On Equity (0.02) |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.